

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL

NEWS EXPRESS May 23 CURRENT WINDOWS VERSION IS V6.0a,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:14:58 ON 21 JUN 2001

=> file medline, uspat, wpids, frosti, embase, dgene, japio, fsta, hcplus, biosis

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:15:31 ON 21 JUN 2001

FILE 'USPATFULL' ENTERED AT 13:15:31 ON 21 JUN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'FROSTI' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 Leathhead Food Research Association

FILE 'EMBASE' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'FSTA' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'HCAPLUS' ENTERED AT 13:15:31 ON 21 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:15:31 ON 21 JUN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

=> s oxazolidinone

L1 8295 OXAZOLIDINONE

=> s elongation factor p

L2 104 ELONGATION FACTOR P

=> s efp

L3 755 EFP

=> s l2 and l3

L4 16 L2 AND L3

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 16 MEDLINE

TI The chvH locus of Agrobacterium encodes a homologue of an elongation factor involved in protein synthesis.

AB The virulence of Agrobacterium tumefaciens depends on both chromosome- and

Ti plasmid-encoded gene products. In this study, we characterize a chromosomal locus, chvH, previously identified by TnphoA mutagenesis and shown to be required for tumor formation. Through DNA sequencing and comparison of the sequence with identified sequences in the database, we show that this locus encodes a protein similar in sequence to **elongation factor P**, a protein thought to be involved in peptide bond synthesis in Escherichia coli. The analysis of vir-lacZ and vir-phoA translational fusions as well as Western immunoblotting revealed that the expression of Vir proteins such as VirE2 was significantly reduced in the chvH mutant compared with the wild-type strain. The E. coli **efp** gene complemented detergent sensitivity, virulence, and expression of VirE2 in the chvH mutant, suggesting that chvH and **efp** are functionally homologous. As expected, ChvH exerts its activity at the posttranscriptional level. Southern analysis suggests that the gene encoding this elongation factor is present as a single copy in A. tumefaciens. We constructed a chvH deletion mutant in which a 445-bp fragment within its coding sequence was deleted and

replaced with an omega fragment. On complex medium, this mutant grew more slowly than the wild-type strain, indicating that **elongation factor P** is important but not essential for the growth of *Agrobacterium*.

ACCESSION NUMBER: 2001086878 MEDLINE
DOCUMENT NUMBER: 20566665 PubMed ID: 11114898
TITLE: The *chvH* locus of *Agrobacterium* encodes a homologue of an elongation factor involved in protein synthesis.
AUTHOR: Peng W T; Banta L M; Charles T C; Nester E W
CORPORATE SOURCE: Department of Microbiology, University of Washington, Seattle, Washington 98195-7242, USA.
CONTRACT NUMBER: GM32618 (NIGMS)
SOURCE: JOURNAL OF BACTERIOLOGY, (2001 Jan) 183 (1) 36-45.
Journal code: HH3. ISSN: 0021-9193.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF177860
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered PubMed: 20001229
Entered Medline: 20010118

L4 ANSWER 2 OF 16 MEDLINE

TI The gene encoding the **elongation factor P** protein is essential for viability and is required for protein synthesis.

AB **Elongation factor P (EFP)** is a protein that stimulates the peptidyltransferase activity of fully assembled 70 S prokaryotic ribosomes and enhances the synthesis of certain

dipeptides initiated by N-formylmethionine. This reaction appears conserved throughout species and is promoted in eukaryotic cells by a homologous protein, eIF5A. Here we ask whether the *Escherichia coli* gene encoding **EFP** is essential for cell viability. A kanamycin resistance (KanR) gene was inserted near the N-terminal end of the **efp** gene and was cloned into a plasmid, pMAK705, that has a temperature-sensitive origin of replication. After transformation into a *recA+* *E. coli* strain, temperature-sensitive mutants were isolated, and their chromosomal DNA was sequenced. Mutants containing the **efp**-KanR gene in the chromosome grew at 33 degrees C only in the presence of the wild-type copy of the **efp** gene in the pMAK705 plasmid and were unable to grow at 44 degrees C. Incorporation of various isotopes in vivo suggests that translation is impaired in the **efp** mutant at 44 degrees C. At 44 degrees C, mutant cells are severely defective in peptide-bond formation. We conclude that the **efp** gene is essential for cell viability and is required for protein synthesis.

ACCESSION NUMBER: 1998070395 MEDLINE
DOCUMENT NUMBER: 98070395 PubMed ID: 9405429
TITLE: The gene encoding the **elongation factor P** protein is essential for viability and is required for protein synthesis.
AUTHOR: Aoki H; Dekany K; Adams S L; Ganoza M C
CORPORATE SOURCE: Banting and Best Department of Medical Research, Nucleic Acids, Protein Synthesis and Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1L6, Canada.
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 Dec 19) 272 (51) 32254-9.
Journal code: HIV; 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199801
ENTRY DATE: Entered STN: 19980130
Last Updated on STN: 19980130
Entered Medline: 19980122

L4 ANSWER 3 OF 16 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of prokaryotic
elongation factor p (efp) for
screening for compounds which can be used as antibiotics comprises
contacting **efp** with a compound and determining if **efp**
activity is modified.

AN 2000-524303 [47] WPIDS

AB WO 200045177 A UPAB: 20000925

NOVELTY - A method (M1) for identifying a compound which modulates the
activity of **efp** comprises contacting **efp** with a
compound and determining whether the compound modifies activity of
efp.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
following:

(1) a method (M2) for identifying a compound which modulates
efp activity comprising:

(a) contacting a cell containing **efp** with a compound
identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates
efp activity comprising:

(a) contacting a composition comprising **efp**,
N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing
an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a
complex formed through the interaction of **efp**, 30S subunit, 50S,
an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates
efp activity comprising:

(a) contacting **efp** with prokaryotic 30S subunit or 70S
ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound binds to **efp** in
association with the 30S subunit or 70S ribosome or interferes with the
binding of **efp** and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates
efp activity comprising:

(a) contacting **efp** with a composition comprising either 50S
subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled
amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond
reaction;

(5) a method (M6) for identifying a compound which modulates
efp activity comprising:

(a) contacting a cell or composition containing **efp** with a
detectably labelled oxazolidinone compound known to bind **efp**;

(b) contacting the composition or cell with an unlabelled compound;
and

(c) determining whether the unlabelled compound displaces the
labelled oxazolidinone compound from the complex;

(6) a method (M7) for identifying a compound which modulates
efp but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of
prokaryotic **efp** by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA
(Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation

factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the **efp** or cell or cell preparation containing the **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS

DOC. NO. NON-CPI: N2000-387540

DOC. NO. CPI: C2000-155724

TITLE: Identifying a compound which modulates the activity of prokaryotic **elongation factor p (efp)** for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A

PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN

COUNTRY COUNT: 86

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU					
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR					
TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 9942246	A Based on	WO 200045177

PRIORITY APPLN. INFO: US 1999-117473 19990127

L4 ANSWER 4 OF 16 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

TI The chvH locus of Agrobacterium encodes a homologue of an elongation factor involved in protein synthesis.

AB The virulence of Agrobacterium tumefaciens depends on both chromosome- and

Ti plasmid-encoded gene products. In this study, we characterize a chromosomal locus *chvH*, previously identified by *TnpHoA* mutagenesis and shown to be required for tumor formation. Through sequencing and comparison of the sequence with identified sequences in the database, we show that this locus encodes a protein similar in sequence to **elongation factor P**, a protein thought to be involved in peptide bond synthesis in *Escherichia coli*. The analysis of *vir-lacZ* and *vir-phoA* translational fusions as well as Western immunoblotting revealed that the expression of Vir proteins such as VirE2 was significantly reduced in the *chvH* mutant compared with the wild-type strain. The *E. coli efp* gene complemented detergent sensitivity, virulence, and expression of VirE2 in the *chvH* mutant, suggesting that *chvH* and *efp* are functionally homologous. As expected, *ChvH* exerts its activity at the posttranscriptional level. Southern analysis suggests that the gene encoding this elongation factor is present as a single copy in *A. tumefaciens*. We constructed a *chvH* deletion mutant in which a 445-bp fragment within its coding sequence was deleted and replaced with an omega fragment. On complex medium, this mutant grew more slowly than the wild-type strain, indicating that **elongation factor P** is important but not essential for the growth of *Agrobacterium*.

ACCESSION NUMBER: 2001002700 EMBASE
 TITLE: The *chvH* locus of *Agrobacterium* encodes a homologue of an elongation factor involved in protein synthesis.
 AUTHOR: Peng W.-T.; Banta L.M.; Charles T.C.; Nester E.W.
 CORPORATE SOURCE: E.W. Nester, Department of Microbiology, Box 357242, University of Washington, Seattle, WA 98195-7242, United States. gmaster@u.washington.edu
 SOURCE: Journal of Bacteriology, (2001) 183/1 (36-45).
 Refs: 55
 ISSN: 0021-9193 CODEN: JOBAA
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 004 Microbiology
 LANGUAGE: English
 SUMMARY LANGUAGE: English

L4 ANSWER 5 OF 16 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

TI The gene encoding the **elongation factor P** protein is essential for viability and is required for protein synthesis.

AB **Elongation factor P (EFP)** is a protein that stimulates the peptidyltransferase activity of fully assembled 70 S prokaryotic ribosomes and enhances the synthesis of certain

dipeptides initiated by N- formylmethionine. This reaction appears conserved throughout species and is promoted in eukaryotic cells by a homologous protein, eIF5A. Here we ask whether the *Escherichia coli* gene encoding **EFP** is essential for cell viability. A kanamycin resistance (Kan(R)) gene was inserted near the N- terminal end of the *efp* gene and was cloned into a plasmid, pMAK705, that has a temperature-sensitive origin of replication. After transformation into a *recA+* *E. coli* strain, temperature-sensitive mutants were isolated, and their chromosomal DNA was sequenced. Mutants containing the *efp* -Kan(R) gene in the chromosome grew at 33 .degree.C only in the presence of the wild-type copy of the *efp* gene in the pMAK705 plasmid and were unable to grow at 44 .degree.C. Incorporation of various isotopes in vivo suggests that translation is impaired in the *efp* mutant at 44 .degree.C. At 44 .degree.C, mutant cells are severely defective in peptide-bond formation. We conclude that the *efp* gene is essential for cell viability and is required for protein synthesis.

ACCESSION NUMBER: 1998006933 EMBASE
 TITLE: The gene encoding the **elongation factor P** protein is essential for viability and is

required for protein synthesis.
AUTHOR: Aoki M.; Dekany K.; Adams S.-L.; Ganoza M.C.
CORPORATE SOURCE: M.C. Ganoza, C.H. Best Institute, University of Toronto,
Toronto, Ont. M5G 1L6, Canada. m.ganoza@utoronto.ca
SOURCE: Journal of Biological Chemistry, (1997) 272/51
(32254-32259).
Refs: 42
ISSN: 0021-9258 CODEN: JBCHA3
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

L4 ANSWER 6 OF 16 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of prokaryotic
elongation factor p (efp) for
screening for compounds which can be used as antibiotics comprises
contacting **efp** with a compound and determining if **efp**
activity is modified -
AB The present sequence is the Escherichia coli **elongation**
factor p (efp), which comprises part of the
prokaryotic ribosomal complex. It can be used in the methods of the
invention to identify compounds which interfere with ribosomal peptide
bond synthesis, which can then be used as antimicrobial agents. These
compounds may modulate interactions between any of the ribosomal
subunits, including the 30S and 50S subunits, as well as factors such as
efp and L16. They can also be used to identify compounds which
modulate the activity of **efp** but do not have any effect on its
mammalian analogue eIF5A.

ACCESSION NUMBER: AAB21122 protein DGENE
TITLE: Identifying a compound which modulates the activity of
prokaryotic **elongation factor p**
(**efp**) for screening for compounds which can be used
as antibiotics comprises contacting **efp** with a
compound and determining if **efp** activity is
modified -
INVENTOR: Poorman R A; Wells P A; Marotti K R; Shinabarger D L
PATENT ASSIGNEE: (PHAA) PHARMACIA & UPJOHN.
PATENT INFO: WO 2000045177 A1 20000803 52p
APPLICATION INFO: WO 1999-US12073 19990528
PRIORITY INFO: US 1999-117473 19990127
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-524303 [47]

L4 ANSWER 7 OF 16 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of prokaryotic
elongation factor p (efp) for
screening for compounds which can be used as antibiotics comprises
contacting **efp** with a compound and determining if **efp**
activity is modified -
AB The present sequence is the Staphylococcus aureus **elongation**
factor p (efp), which comprises part of the
prokaryotic ribosomal complex. It can be used in the methods of the
invention to identify compounds which interfere with ribosomal peptide
bond synthesis, which can then be used as antimicrobial agents. These
compounds may modulate interactions between any of the ribosomal
subunits, including the 30S and 50S subunits, as well as factors such as
efp and L16. They can also be used to identify compounds which
modulate the activity of **efp** but do not have any effect on its
mammalian analogue eIF5A.
ACCESSION NUMBER: AAB21121 protein DGENE
TITLE: Identifying a compound which modulates the activity of

prokaryotic **elongation factor p**
(**efp**) for screening for compounds which can be used
as antibiotics comprises contacting **efp** with a
compound and determining if **efp** activity is
modified -

INVENTOR: Poorman R A; Wells P A; Marotti K R; Shinabarger D L
PATENT ASSIGNEE: (PHAA) PHARMACIA & UPJOHN.
PATENT INFO: WO 2000045177 A1 20000803 52p
APPLICATION INFO: WO 1999-US12073 19990528
PRIORITY INFO: US 1999-117473 19990127
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-524303 [47]

L4 ANSWER 8 OF 16 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of prokaryotic
elongation factor p (efp) for
screening for compounds which can be used as antibiotics comprises
contacting **efp** with a compound and determining if **efp**
activity is modified -

AB The present sequence is an oligoribonucleotide used in an initiation
complex assay to determine the effects of the presence and absence of
the

Staphylococcus aureus or Escherichia coli **elongation**
factor p (efp). This protein comprises part
of the prokaryotic ribosomal complex. It can be used in the methods of
the invention to identify compounds which interfere with ribosomal
peptide bond synthesis, which can then be used as antimicrobial agents.
These compounds may modulate interactions between any of the ribosomal
subunits, including the 30S and 50S subunits, as well as factors such as
efp and L16. They can also be used to identify compounds which
modulate the activity of **efp** but do not have any effect on its
mammalian analogue eIF5A.

ACCESSION NUMBER: AAA76244 mRNA DGENE
TITLE: Identifying a compound which modulates the activity of
prokaryotic **elongation factor p**
(**efp**) for screening for compounds which can be used
as antibiotics comprises contacting **efp** with a
compound and determining if **efp** activity is
modified -

INVENTOR: Poorman R A; Wells P A; Marotti K R; Shinabarger D L
PATENT ASSIGNEE: (PHAA) PHARMACIA & UPJOHN.
PATENT INFO: WO 2000045177 A1 20000803 52p
APPLICATION INFO: WO 1999-US12073 19990528
PRIORITY INFO: US 1999-117473 19990127
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-524303 [47]

L4 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2001 ACS
TI Crystallization and structure determination of Staphylococcus aureus
elongation factor P

AB Staphylococcus aureus **elongation factor P**
(S. aureus EF-P) was crystd., and the 3-dimensional x-ray crystal
structure solved to 1.9 A resolu. EF-P crystals belong to the
orthorhombic space group symmetry P212121, with dimensions of a = 25-50,

b
= 35-60, c = 85-110 .ANG. and .alpha. = .beta. = .gamma. = 90.degree..
The x-ray crystal structure is useful for solving the structure of other
mols. or mol. complexes, and designing inhibitors of S. aureus EF-P.

ACCESSION NUMBER: 2001:115188 HCAPLUS
DOCUMENT NUMBER: 134:159195
TITLE: Crystallization and structure determination of
Staphylococcus aureus **elongation**

INVENTOR(S): **Factor P** Benson, Timothy E.
 PATENT ASSIGNEE(S): Pharmacia and Upjohn Company, U
 SOURCE: PCT Int. Appl., 289 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010906	A1	20010215	WO 2000-US21528	20000804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-147851 P 19990806

REFERENCE COUNT: 9

REFERENCE(S):

- (1) Aoki, H; BIOCHIMIE (PARIS) 1997, V79(1), P7 HCAPLUS
- (2) Aoki, H; JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(51), P32254 HCAPLUS
- (4) Kim, K; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES 1998, V95(18), P10419 HCAPLUS
- (7) Marotti, K; WO 0045177 A 2000 HCAPLUS
- (9) Zhou, Q; EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL 1998, V17(13), P3681

HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2001 ACS

TI The chvH locus of Agrobacterium encodes a homologue of an elongation factor involved in protein synthesis

AB The virulence of Agrobacterium tumefaciens depends on both chromosome- and

Ti plasmid-encoded gene products. In this study, we characterize a chromosomal locus, chvH, previously identified by TnphoA mutagenesis and shown to be required for tumor formation. Through DNA sequencing and comparison of the sequence with identified sequences in the database, we show that this locus encodes a protein similar in sequence to **elongation factor P**, a protein thought to be involved in peptide bond synthesis in Escherichia coli. The anal. of vir-lacZ and vir-phoA translational fusions as well as Western immunoblotting revealed that the expression of Vir proteins such as VirE2 was significantly reduced in the chvH mutant compared with the wild-type strain. The E. coli **efp** gene complemented detergent sensitivity, virulence, and expression of VirE2 in the chvH mutant, suggesting that chvH and **efp** are functionally homologous. As expected, ChvH exerts its activity at the posttranscriptional level. Southern anal. suggests that the gene encoding this elongation factor is present as a single copy in A. tumefaciens. We constructed a chvH deletion mutant in which a 445-bp fragment within its coding sequence was deleted and replaced with an omega fragment. On complex medium, this mutant grew more slowly than the wild-type strain, indicating that **elongation factor P** is important but not essential for the growth of Agrobacterium.

ACCESSION NUMBER: 2001:11527 HCAPLUS

TITLE: The chvH locus of Agrobacterium encodes a homologue
of
an elongation factor involved in protein synthesis
AUTHOR(S): Peng, Wen-Tao; Banta, Lois M.; Charles, Trevor C.;
Nester, Eugene W.
CORPORATE SOURCE: Department of Microbiology, University of Washington,
Seattle, WA, 98195-7242, USA
SOURCE: J. Bacteriol. (2001), 183(1), 36-45
CODEN: JOBAAAY; ISSN: 0021-9193
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 55
REFERENCE(S): (1) Abratt, V; Mol Gen Genet 1998, V258, P363 HCAPLUS
(2) Aoki, H; J Biol Chem 1997, V272, P32254 HCAPLUS
(3) Aoki, H; Nucleic Acids Res 1991, V19, P6215
HCAPLUS
(6) Banta, L; J Bacteriol 1998, V180, P6597 HCAPLUS
(7) Becker, A; Gene 1995, V162, P37 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2001 ACS

TI Re-annotating the Mycoplasma pneumoniae genome sequence: adding value,
function and reading frames

AB Four years after the original sequence submission, we have re-annotated
the genome of Mycoplasma pneumoniae to incorporate novel data. The total
no. of ORFss has been increased from 677 to 688 (10 new proteins were
predicted in intergenic regions, two further were newly identified by

mass spectrometry and one protein ORF was dismissed) and the no. of RNAs from
39 to 42 genes. For 19 of the now 35 tRNAs and for six other functional
RNAs the exact genome positions were re-annotated and two new tRNA^{Leu} and
a small 200 nt RNA were identified. Sixteen protein reading frames were
extended and eight shortened. For each ORF a consistent annotation
vocabulary has been introduced. Annotation reasoning, annotation
categories and comparisons to other published data on M. pneumoniae
functional assignments are given. Exptl. evidence includes 2-dimensional
gel electrophoresis in combination with mass spectrometry as well as gene
expression data from this study. Compared to the original annotation, we
increased the no. of proteins with predicted functional features from 349
to 458. The increase includes 36 new predictions and 73 protein
assignments confirmed by the published literature. Furthermore, there

are 23 redns. and 30 addns. with respect to the previous annotation. MRNA
expression data support transcription of 184 of the functionally
unassigned reading frames.

ACCESSION NUMBER: 2000:679263 HCAPLUS

DOCUMENT NUMBER: 134:188814

TITLE: Re-annotating the Mycoplasma pneumoniae genome
sequence: adding value, function and reading frames

AUTHOR(S): Dandekar, Thomas; Huynen, Martijn; Regula, Jorg
Thomas; Ueberle, Barbara; Zimmermann, Carl Ulrich;
Andrade, Miguel A.; Doerks, Tobias; Sanchez-Pulido,
Luis; Snel, Berend; Suyama, Mikita; Yuan, Yan P.;
Herrmann, Richard; Bork, Peer

CORPORATE SOURCE: EMBL, Heidelberg, D-69012, Germany

SOURCE: Nucleic Acids Res. (2000), 28(17), 3278-3288

CODEN: NARHAD; ISSN: 0305-1048

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 44

REFERENCE(S): (1) Altschul, S; Nucleic Acids Res 1997, V25, P3389
HCAPLUS

(2) Aravind, L; Trends Biochem Sci 1998, V23, P17
HCAPLUS
(3) Bellgard, M; Gene 1999, V233, P33 HCAPLUS
(4) Bork, P; J Mol Biol 1998, V283, P707 HCAPLUS
(5) Bork, P; Methods Enzymol 1996, V266, P162 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2001 ACS
TI Assays for modulators of **elongation factor p**
activity
AB Disclosed are novel methods of using **elongation factor p (efp)** and related constituents of ribosomal complexes which comprise **efp**, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compds. which modulate prokaryotic **elongation factor p** and modify cell function are described. Both in vitro and in vivo methods for identifying compds. which modulate such constituents and affect cell function are described. Such identified compds., including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compds., and antiseptics contg. such compds. are described. The present invention is also directed to methods and compds. that modulate prokaryotic **elongation factor p**.
ACCESSION NUMBER: 2000:535370 HCAPLUS
DOCUMENT NUMBER: 133:144893
TITLE: Assays for modulators of **elongation factor p** activity
INVENTOR(S): Poorman, Roger A.; Wells, Peter Andrew; Marotti, Keith
R.; Shinabarger, Dean L.
PATENT ASSIGNEE(S): Pharmacia and Upjohn, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045177	A1	20000803	WO 1999-US12073	19990528
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9942246	A1	20000818	AU 1999-42246	19990528
PRIORITY APPLN. INFO.:			US 1999-117473	P 19990127
			WO 1999-US12073	W 19990528
REFERENCE COUNT:		4		
REFERENCE(S):		(1) Anon; 1998, 13, HCAPLUS (2) Anon; 1999, 10, HCAPLUS (3) Aoki, H; JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(51), P32254 HCAPLUS (4) Swaney, S; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 1998, V42(12), P3251 HCAPLUS		

L4 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2001 ACS
TI The gene encoding the **elongation factor P**

protein is essential for viability and is required for protein synthesis

AB **Elongation factor (EF-P)** is a protein that stimulates the peptidyltransferase activity of fully assembled 70 S prokaryotic ribosomes and enhances the synthesis of certain dipeptides initiated by N-formylmethionine. This reaction appears conserved throughout species and is promoted in eukaryotic cells by a homologous protein, eIF5A. Here we ask whether the *Escherichia coli* gene encoding **EF-P** is essential for cell viability. A kanamycin resistance (KanR) gene was inserted near the N-terminal end of the **efp** gene and was cloned into a plasmid, pMAK705, that has a temp.-sensitive origin of replication. After transformation into a *recA*⁺ *E. coli* strain, temp.-sensitive mutants were isolated, and their chromosomal DNA was sequenced. Mutants containing the **efp**-KanR gene in the chromosome grew at 33°C only in the presence of the wild-type copy of the **efp** gene in the pMAK705 plasmid and were unable to grow at 44°C. Incorporation of various isotopes in vivo suggests that translation is impaired in the **efp** mutant at 44°C. At 44°C, mutant cells are severely defective in peptide-bond formation. We conclude that the **efp** gene is essential for cell viability and is required for protein synthesis.

ACCESSION NUMBER: 1998:26675 HCAPLUS
 DOCUMENT NUMBER: 128:151566
 TITLE: The gene encoding the **elongation factor P** protein is essential for viability and is required for protein synthesis
 AUTHOR(S): Aoki, Hiroyuki; Dekany, Katalin; Adams, Sally-Lin; Ganoza, M. Clelia
 CORPORATE SOURCE: Banting and Best Department of Medical Res., Nucleic Acids, Protein Synthesis and Molecular Genetics, Univ. Toronto, Toronto, ON, M5G 1L6, Can.
 SOURCE: J. Biol. Chem. (1997), 272(51), 32254-32259
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L4 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2001 ACS
 TI Cloning, sequencing and overexpression of the gene for prokaryotic factor EF-P involved in peptide bond synthesis
 AB A sol. protein EF-P (**elongation factor P**) from *Escherichia coli* has been purified and shown to stimulate efficient translation and peptide-bond synthesis on native or reconstituted 70 S ribosomes in vitro. Based on the partial amino acid sequence of EF-P, 18- and 24-nucleotide DNA probes were synthesized and used to screen λ phage clones from the Kohara Gene Bank. The entire EF-P gene was detected on λ clone #650, which contains sequences from the 94 min region of the *E. coli* genome. Two DNA fragments, 3.0 and 0.78 kilobases in length encompassing the gene, were isolated and cloned into pUC18 and pUC19. Partially purified exts. from cells transformed with these plasmids overrepresented a protein which comigrates with EF-P upon SDS-PAGE, and also exhibited increased EF-P mediated peptide-bond synthetic activity. Based on DNA sequence anal. of this gene, the EF-P protein consists of 187 amino acids with a calcd. mol. wt. of 20,447. The sequence and chromosomal location of EF-P establishes it as a unique gene product.

ACCESSION NUMBER: 1993:2559 HCAPLUS
 DOCUMENT NUMBER: 118:2559

TITLE: Cloning, sequencing and overexpression of the gene
for prokaryotic factor EF-P involved in peptide bond
synthesis
AUTHOR(S): Aoki, Hiroyuki; Adams, Sally Lin; Chung, Dae Gyun;
Yaguchi, Makoto; Chuang, Shuang En; Ganoza, M. Clelia
CORPORATE SOURCE: Banting and Best Dep. Med. Res., Univ. Toronto,
Toronto, ON, Can.
SOURCE: Nucleic Acids Res. (1991), 19(22), 6215-20
CODEN: NARHAD; ISSN: 0305-1048
DOCUMENT TYPE: Journal
LANGUAGE: English

L4 ANSWER 15 OF 16 BIOSIS COPYRIGHT 2001 BIOSIS

TI The chvH locus of Agrobacterium encodes a homologue of an elongation
factor involved in protein synthesis.

AB The virulence of Agrobacterium tumefaciens depends on both chromosome-
and

Ti plasmid-encoded gene products. In this study, we characterize a
chromosomal locus, chvH, previously identified by TnphoA mutagenesis and
shown to be required for tumor formation. Through DNA sequencing and
comparison of the sequence with identified sequences in the database, we
show that this locus encodes a protein similar in sequence to
elongation factor P, a protein thought to be
involved in peptide bond synthesis in Escherichia coli. The analysis of
vir-lacZ and vir-phoA translational fusions as well as Western
immunoblotting revealed that the expression of Vir proteins such as VirE2
was significantly reduced in the chvH mutant compared with the wild-type
strain. The E. coli **efp** gene complemented detergent sensitivity,
virulence, and expression of VirE2 in the chvH mutant, suggesting that
chvH and **efp** are functionally homologous. As expected, ChvH
exerts its activity at the posttranscriptional level. Southern analysis
suggests that the gene encoding this elongation factor is present as a
single copy in A. tumefaciens. We constructed a chvH deletion mutant in
which a 445-bp fragment within its coding sequence was deleted and
replaced with an omega fragment. On complex medium, this mutant grew more
slowly than the wild-type strain, indicating that **elongation**
factor P is important but not essential for the growth
of Agrobacterium.

ACCESSION NUMBER: 2001:61207 BIOSIS

DOCUMENT NUMBER: PREV200100061207

TITLE: The chvH locus of Agrobacterium encodes a homologue of an
elongation factor involved in protein synthesis.

AUTHOR(S): Peng, Wen-Tao; Banta, Lois M.; Charles, Trevor C.; Nester,
Eugene W. (1)

CORPORATE SOURCE: (1) Department of Microbiology, University of Washington,
Seattle, WA, 98195-7242; gnester@u.washington.edu USA

SOURCE: Journal of Bacteriology, (January, 2001) Vol. 183, No. 1,
pp. 36-45. print.
ISSN: 0021-9193.

DOCUMENT TYPE: Article

LANGUAGE: English

SUMMARY LANGUAGE: English

L4 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2001 BIOSIS

TI The gene encoding the **elongation factor P**
protein is essential for viability and is required for protein
synthesis.

AB **Elongation factor P (EFP)** is a
protein that stimulates the peptidyltransferase activity of fully
assembled 70 S prokaryotic ribosomes and enhances the synthesis of
certain
dipeptides initiated by N-formylmethionine. This reaction appears
conserved throughout species and is promoted in eukaryotic cells by a

homologous protein, eIF5A. Here we ask whether the Escherichia coli gene encoding **EFp** is essential for cell viability. A kanamycin resistance (KanR) gene was inserted near the N-terminal end of the **efp** gene and was cloned into a plasmid, pMAK705, that has a temperature-sensitive origin of replication. After transformation into a recA+ E. coli strain, temperature-sensitive mutants were isolated, and their chromosomal DNA was sequenced. Mutants containing the **efp**-KanR gene in the chromosome grew at 33degree C only in the presence of the wild-type copy of the **efp** gene in the pMAK705 plasmid and were unable to grow at 44degree C. Incorporation of various isotopes in vivo suggests that translation is impaired in the **efp** mutant at 44degree C. At 44degree C, mutant cells are severely defective in peptide-bond formation. We conclude that the **efp** gene is essential for cell viability and is required for protein synthesis.

ACCESSION NUMBER: 1998:83503 BIOSIS
DOCUMENT NUMBER: PREV199800083503
TITLE: The gene encoding the **elongation factor**
P protein is essential for viability and is required for protein synthesis.
AUTHOR(S): Aoki, Hiroyuki; Dekany, Katalin; Adams, Sally-Lin; Ganoza, M. Clelia (1)
CORPORATE SOURCE: (1) C.H. Best Inst., Univ. Toronto, Toronto, ON M5G 1L6 Canada
SOURCE: Journal of Biological Chemistry, (Dec. 19, 1997) Vol. 272, No. 51, pp. 32254-32259.
ISSN: 0021-9258.
DOCUMENT TYPE: Article
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 13:14:58 ON 21 JUN 2001)

FILE 'MEDLINE, USPATFULL, WPIDS, FROSTI, EMBASE, DGENE, JAPIO, FSTA, HCAPLUS, BIOSIS' ENTERED AT 13:15:31 ON 21 JUN 2001

L1 8295 S OXAZOLIDINONE
L2 104 S ELONGATION FACTOR P
L3 755 S EFP
L4 16 S L2 AND L3

=> s l3 and l1

L5 2 L3 AND L1

=> d l5 ti abs ibib t

'T' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 2 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of prokaryotic elongation factor p (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.

NOVELTY - A method (M1) for identifying a compound which modulates the activity of **efp** comprises contacting **efp** with a compound and determining whether the compound modifies activity of **efp**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell containing **efp** with a compound identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a composition comprising **efp**, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of **efp**, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound binds to **efp** in association with the 30S subunit or 70S ribosome or interferes with the binding of **efp** and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell or composition containing **efp** with a detectably labelled **oxazolidinone** compound known to bind **efp**;

(b) contacting the composition or cell with an unlabelled compound; and

(c) determining whether the unlabelled compound displaces the labelled **oxazolidinone** compound from the complex;

(6) a method (M7) for identifying a compound which modulates **efp** but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of prokaryotic **efp** by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the **efp** or cell or cell preparation containing the **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an **oxazolidinone** compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS
DOC. NO. NON-CPI: N2000-387540
DOC. NO. CPI: C2000-155724
TITLE: Identifying a compound which modulates the activity of prokaryotic elongation factor p (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN
COUNTRY COUNT: 86
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942246	A Based on	WO 200045177

PRIORITY APPLN. INFO: US 1999-117473 19990127

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS

TI Assays for modulators of elongation factor p activity

AB Disclosed are novel methods of using elongation factor p (**efp**) and related constituents of ribosomal complexes which comprise **efp**, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation

complex, and related proteins, cofactors and enzymes. Methods of identifying compds. which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for

identifying compds. which modulate such constituents and affect cell function are described. Such identified compds., including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compds., and antiseptics contg. such compds. are described. The present invention is also directed to methods and compds. that modulate prokaryotic elongation factor p.

ACCESSION NUMBER: 2000:535370 HCAPLUS
DOCUMENT NUMBER: 133:144893

TITLE: Assays for modulators of elongation factor p activity
 INVENTOR(S): Poorman, Roger A.; Wells, Peter Andrew; Marotti,
 Keith
 R.; Shinabarger, Dean L.
 PATENT ASSIGNEE(S): Pharmacia and Upjohn, USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045177	A1	20000803	WO 1999-US12073	19990528
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9942246	A1	20000818	AU 1999-42246	19990528
PRIORITY APPLN. INFO.:			US 1999-117473	P 19990127
			WO 1999-US12073	W 19990528

REFERENCE COUNT: 4
 REFERENCE(S):
 (1) Anon; 1998, 13, HCAPLUS
 (2) Anon; 1999, 10, HCAPLUS
 (3) Aoki, H; JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(51), P32254 HCAPLUS
 (4) Swaney, S; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 1998, V42(12), P3251 HCAPLUS